Alterity Therapeutics: Appoints Dr David Stamler as CEO

  • Alterity Therapeutics (ATH) has appointed Dr. David Stamler as CEO, effective immediately
  • Dr. Stamler has been with the company since June 2017, previously serving as Chief Medical Officer and Senior Vice President Clinical Development
  • It’s a great privilege to work towards improving the lives of millions of people suffering from neurodegenerative diseases,” Geoffrey said
  • He has significant experience in pharmaceutical development and commercialization
  • Dr. Stamler will replace former CEO Geoffrey Kempler, who will continue as Non-Executive Chairman
  • Alterity is up 3.23 percent on the market and shares are currently trading at 3.2 cents
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

One in Seven UK High Street Shops Adopt Cashless Payments

New survey reveals a significant shift towards cashless transactions.Highlights: One in seven UK high street shops went cashless...

Morgan Stanley to Cut 2,500 Staff Across Divisions

The bank aims to streamline operations amidst economic uncertainties.Highlights: Morgan Stanley plans to cut 2,500 jobs across various...

Lloyds to Sell Customer Data to Cut IT Costs and Strengthen Fintech Position

The bank aims to optimize operations and enhance its fintech offerings.Highlights: Lloyds is selling customer data to reduce...

Robinhood Launches $695 Annual Platinum Credit Card, Challenging Amex

The new offering aims to disrupt the premium credit card market.Highlights: Robinhood's new Platinum credit card costs $695...